Boston Children's Hospital is monitoring the developing situation with lead contamination in some Boston Public Schools. Please contact your primary care physician if you have any concerns about your child.
Boston Children’s Hospital está monitoreando la situación de la contaminación por plomo en algunas escuelas públicas de Boston. Por favor, póngase en contacto con su médico primario si usted tiene alguna preocupación acerca de su hijo.
Ranked #1 Children's Hospital by U.S. News & World Report
MyPatients provides referring primary care providers with secure access to their patients’ information.
Boston Children's has launched the world's 1st program dedicated to offering hand transplants to children who qualify.
Innovation insider is a semi-monthly e-newsletter analyzes innovations at Boston Children’s, other academic medical centers and from industry.
Read the latest blog by a Boston Children's doctor, clinician or staff member.
Support the hospital with a donation that helps kids get the care they need.
Skin and soft tissue infections (SSTIs) caused by MRSA (methicillin resistant staphylococcal aureus) have become increasingly common over the past 15-20 years. Defined by resistance to methicillin with an MIC>= 4mcg/mL, MRSA strains are resistant to all beta lactam antibiotics except for fourth-generation cephalosporins, such as ceftaroline.
Historically, MRSA was primarily a health care-associated pathogen, but in the mid-late 1990s the emergence of so-called community-associated MRSA strains led to a dramatic increase in MRSA infections in otherwise healthy patients. The spectrum of MRSA infections ranges from asymptomatic colonization to SSTIs to more invasive infections such as osteomyelitis, bacteremia and endocarditis. SSTIs are the most common presentation, accounting for up to 96 percent of MRSA infections in children.
A diagnostic challenge is determining when an SSTI is caused by MRSA. MRSA SSTIs often begin looking like a spider bite and then progress to a pustule or deeper abscess, but these may be indistinguishable from SSTIs caused by MSSA (methicillin-sensitive staphylococcus aureus) or other pathogens.
A history of MRSA infections in the patient or in family or other close contacts may provide a clue for the etiology. Culture of purulent material from a lesion is optimal in providing a diagnosis.
Incision and drainage (I and D) is the mainstay of treatment of MRSA abscess and boils. Smaller lesions less than 5 cm may be managed by I and D alone, while antibiotics are recommended for severe or more extensive disease, areas of involvement such as the face which may be difficult to drain, rapid progression, systemic illness or other risk factors such as extremes of age or immunosuppression.
Empiric antibiotic choice depends on several factors, including severity of illness and likelihood of MRSA. For outpatients with an abscess or purulent cellulitis, empiric coverage with trimethoprim-sulfamethoxazole, clindamycin or, for older patients, doxycycline is often used, as most MRSA and MSSA strains are susceptible to those agents.
Recurrent SSTIs due to MRSA can be problematic. Prevention strategies endorsed by the U.S. Centers for Disease Control and Prevention and Infectious Diseases Society of America include focus on personal and environmental hygiene. Patients and parents should be counseled to cover draining wounds, hand wash frequently and avoid sharing personal items with others, such as towels and bar soaps. In addition, because of the potential contribution of MRSA colonization to recurrent MRSA infection, decolonization may be advised, usually with daily nasal mupirocin in combination with topical chlorhexidine or bleach baths for a period of five to 10 days. Occasionally, an oral antibiotic course with a first-line antibiotic combined with rifampin, may be used in combination with topical decolonization attempts.
Patients with recurrent infections may be referred to Boston Children’s Hospital Infectious Diseases Clinic for evaluation, counseling and education about prevention of recurrent MRSA SSTIs.
The future of pediatrics will be forged by thinking differently, breaking paradigms and joining together in a shared vision of tackling the toughest challenges before us.”